Atea Pharmaceuticals, Inc. (AVIR)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Unrealized loss on available-for-sale investments | -81 | 921 | ||
| Income tax expense | 207 | 226 | ||
| Research and development | 32,275 | 26,159 | ||
| General and administrative | 9,070 | 11,043 | ||
| Total operating expenses | 41,345 | 37,202 | ||
| Loss from operations | -41,345 | -37,202 | ||
| Interest income and other, net | 4,391 | 6,277 | ||
| Loss before income taxes | -36,954 | -30,925 | ||
| Net loss | -37,161 | -31,151 | ||
| Comprehensive loss | -37,242 | -30,230 | ||
| Net loss per share - basic | -0.44 | -0.37 | ||
| Net loss per share - diluted | -0.44 | -0.37 | ||
| Weighted-average number of common shares - basic | 83,747,335 | 84,422,000 | ||
| Weighted-average number of common shares - diluted | 83,747,335 | 84,422,000 | ||